Analysts Set Altimmune, Inc. (NASDAQ:ALT) Price Target at $20.83

Altimmune, Inc. (NASDAQ:ALT) has been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $20.83.

Several research firms have recently weighed in on ALT. William Blair reissued a “market perform” rating on shares of Altimmune in a report on Friday, March 14th. Stifel Nicolaus initiated coverage on shares of Altimmune in a research note on Wednesday, January 8th. They set a “buy” rating and a $18.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Altimmune in a report on Tuesday, March 18th.

Insider Activity

In related news, CFO Gregory L. Weaver acquired 10,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were purchased at an average cost of $5.20 per share, with a total value of $52,000.00. Following the transaction, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $52,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Altimmune

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALT. Larson Financial Group LLC purchased a new stake in shares of Altimmune in the third quarter worth $31,000. SBI Securities Co. Ltd. purchased a new stake in Altimmune in the 4th quarter worth $45,000. Virtus ETF Advisers LLC bought a new stake in Altimmune during the fourth quarter valued at about $60,000. Cullen Frost Bankers Inc. purchased a new position in shares of Altimmune in the fourth quarter valued at about $72,000. Finally, 180 Wealth Advisors LLC bought a new position in shares of Altimmune in the fourth quarter worth about $78,000. Institutional investors own 78.05% of the company’s stock.

Altimmune Trading Down 4.5 %

Altimmune stock opened at $5.32 on Friday. The firm has a market cap of $409.71 million, a price-to-earnings ratio of -3.43 and a beta of 0.87. Altimmune has a 12 month low of $5.14 and a 12 month high of $11.16. The stock has a fifty day simple moving average of $6.24 and a two-hundred day simple moving average of $7.06.

Altimmune (NASDAQ:ALT) last issued its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. On average, equities research analysts forecast that Altimmune will post -1.35 EPS for the current fiscal year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.